Reviva Pharm Holdings Initiated at Buy by EF Hutton
Maxim Group Maintains Reviva Pharmaceuticals(RVPH.US) With Hold Rating
Maxim Group Reaffirms Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)
Reviva Pharm Holdings Price Target Maintained With a $17.00/Share by Benchmark
Reviva Pharmaceuticals Analyst Ratings
Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Maxim Group Downgrades Reviva Pharmaceuticals(RVPH.US) to Hold Rating
Reviva Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
Reviva Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
Reviva Pharmaceuticals Analyst Ratings
Reviva Pharmaceuticals Analyst Ratings
Reviva Pharmaceuticals Analyst Ratings
Maxim Group Remains a Buy on Reviva Pharmaceuticals Holdings (RVPH)
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
HC Wainwright & Co. : Reviva Pharmaceuticals (RVPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
Reviva Pharmaceuticals Analyst Ratings
Benchmark: Revised Reviva Pharmaceuticals (RVPH.US) rating and adjusted from Speculative Buy to Specified Buy, target price $17.00.
Reviva Pharmaceuticals Analyst Ratings